

TDM-based tailored dosing of durvalumab in lung cancer patients - a comprehensive population pharmacokinetic-pharmacoeconomic evaluation. *Clinical Pharmacokinetics*.

Fenna de Vries^{1,2}, Eric J.F. Franssen, Arthur A.J. Smit, Dirk Jan A.R. Moes, Anthonie J. van der Wekken, Thijs Oude Munnink, Jeroen J.M.A. Hendriks, Daphne W. Dumoulin, Stijn L.W. Koolen, Wietske Kievit, Michel M. van den Heuvel, Rob ter Heine.

¹. Department of Pharmacy, OLVG, Amsterdam, The Netherlands, f.devries@olv.nl.

². Department of Pharmacy, Research Institute for Medical Innovation, Radboudumc, Nijmegen, The Netherlands, fenna.devries1@radboudumc.nl.

SUPPLEMENTAL METHODS

Method S1 Substantiation of costs

All costs included in the pharmacoeconomic analysis and considerations regarding these costs are substantiated in **Table S2**.

Overall, salary costs were determined based on the average salary associated with the position as specified in the collective labor agreements of both a university medical center and a non-university medical center. [20, 22, 23] Social security contributions are calculated based on the following assumptions: the employee holds a permanent contract; receives an 8.33% holiday allowance and 8.33% end-of-year bonus; is subject to employee insurance contributions and income-related contributions under the Dutch Health Insurance Act; and a 1.22% contribution for the Work Resumption Fund, assuming a large employer.

All cost items were adjusted to June 2024 using the consumer price index (CPI) published by Statistics Netherlands (Centraal Bureau voor de Statistiek, CBS). [24]

The correction for the annual rate of change in the CPI was calculated using the following formula:

$$(1) \text{ Cumulative CPI} = \prod_{i=1}^n \text{CPI}$$

Whereby the inflation for 2023 to June 2024 was calculated by:

$$(2) \text{ Inflation factor}_{2023-June\ 2024} = \frac{\text{CPI}_{June\ 2024}}{\text{CPI}_{2023}}$$